pharma · Systemic Lupus Erythematosus
Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals (Deutschland) GmbH
Santhera Pharmaceuticals (Deutschland) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Systemic Lupus Erythematosus. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), an
Pratteln, CH HQ
2004 Founded
115 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Pratteln, CH
- Founded
- 2004
- Employees
- 115
- Programs
- 2
- Drugs
- 1
- Patents
- 0
A-623
Phase 2 · small molecule · Systemic Lupus Erythematosus
A-623 for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at Santhera Pharmaceuticals (Deutschland) GmbH with 1 ClinicalTrials.gov record(s).
Internal code AN-SLE3322
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Santhera Pharmaceuticals (Deutschland) GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Systemic Lupus Erythematosus
- Status
- completed
- Trials
- 1